Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”), the holding subsidiary of the company, has recently initiated phase I/II clinical trials to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics and efficacy of SYS6088 in patients with advanced/metastatic solid tumors.

SYS6088 injection is a recombinant humanized anti-programmed death receptor 1 (PD-1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-related antigen 4 (CTLA-4) antibody with a hexavalent symmetric structure. It can specifically bind PD-1, CTLA-4 on the surface of target cell membranes and VEGFA in the tumor microenvironment to restore the killing function of T cells in the tumor microenvironment, inhibit angiogenesis, and amplify the triple superposition antitumor effect of T cells during the immune activation phase. Modification of the Fc terminal can reduce the risk of toxicity of this product while effectively extending its half-life.

The Phase I/II clinical trial initiated this time is the first human study of SYS6088. It aims to evaluate the safety, tolerability, PK characteristics, and initial anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.